First Pill for Rare Lung Disease Lands $475M Deal

For 40 years, treating a rare genetic lung disease meant weekly IV infusions at a clinic.

Now a pill that blocks 90% of the damaging enzyme just secured a nearly half-billion dollar deal to reach American patients.